Latest
finance.yahoo.com Market update
AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim …
Main company
🇬🇧 United Kingdom
Read at finance.yahoo.com